Compare ACADIA Pharmaceuticals Inc. (ACAD) vs VanEck Australian Floating Rate ETF (FLOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs VanEck Australian Floating Rate ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.73 (market cap $4.49B), while VanEck Australian Floating Rate ETF trades at $50.96. Which is the better fit depends on your goals.
| ACAD | FLOT | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Sector/Thematic |
52-Week High | $28.06 | $51.09 |
52-Week Low | $20.06 | $50.72 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
FLOT trades at $50.96, up 0.08% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The ETF focuses on high-quality floating rate bonds, offering a 4.0% SEC yield, and recent dividends include $0.18 paid in June 2026. News highlights potential Fed rate hikes as a catalyst for yield growth, while credit quality remains strong with minimal default risk.
Outlook is cautious due to bearish technicals and interest rate uncertainty, but FLOT provides a stable income stream with low credit risk. Key risks include inflation-driven rate volatility and economic shifts affecting bond yields, making it suitable for investors seeking short-term cash parking with modest returns above Treasuries.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →
